Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17897037 | 0.86 | MRGPRX4 (0.51) | MRGPRX4CES2RXRARXRBRXRG | |
| SCHEMBL24214278 | 0.85 | MRGPRX4 (0.50) | MRGPRX4CES2RXRARXRBRXRG | |
| SCHEMBL16952850 | 0.83 | CES2 (0.38) | CES2RXRARXRBRXRGTACR1 | |
| SCHEMBL1355567 | 0.82 | ALDH1A1 (0.45) | RXRARXRBALDH1A1 | |
| SCHEMBL7769260 | 0.82 | RXRA (0.46) | RXRARXRBALDH1A1 | |
| SCHEMBL27761970 | 0.81 | RXRA (0.53) | MRGPRX4CES2RXRARXRBRXRG | |
| SCHEMBL17896574 | 0.80 | MRGPRX4 (0.49) | MRGPRX4CES2RXRARXRBRXRG | |
| SCHEMBL2600179 | 0.80 | IDO1 (0.48) | TACR1POLB | |
| SCHEMBL12412585 | 0.80 | IDO1 (0.43) | — | |
| SCHEMBL16727011 | 0.80 | MRGPRX4 (0.55) | MRGPRX4TACR1NOTUMNR4A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150112071-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140256947-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256947-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | MRGPRX4 3622/4885CES2 2724/4885RXRA 4868/4885 |
| US-20150112071-A1 | PREPARATION OF AMINOTETRALIN COMPOUNDS | MAP4K5, MAP4K2, MAP4K1 | MRGPRX4 3622/4885CES2 2724/4885RXRA 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.